Determination of the Aβ42/Aβ40 ratio by ABtest-MS in a subgroup of 74 MCI patient samples from the phase II trial of ABvac40 (active anti-Aβ40 vaccine).
The Aβ42/Aβ40 ratio in plasma differs significantly between amyloid-PET positive and negative individuals (P <0.0001).
The Aβ42/Aβ40 ratio in plasma discriminates positive and negative amyloid-PET with high accuracy (AUC = 0.872; 0.881 for the model adjusted for APoE genotype) and balanced sensitivity (80.4%) and specificity (94.4%) values.
